# Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants

> **NCT03041116** · PHASE3 · TERMINATED · sponsor: **Travere Therapeutics, Inc.** · enrollment: 84 (actual)

## Conditions studied

- Pantothenate Kinase-Associated Neurodegeneration

## Interventions

- **DRUG:** Fosmetpantotenate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03041116
- **Lead sponsor:** Travere Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-17
- **Primary completion:** 2019-12-30
- **Final completion:** 2019-12-30
- **Target enrollment:** 84 (ACTUAL)
- **Why stopped:** The study was terminated since fosmetpantotenate did not show statistically significant effects or clinical benefits during the double-blind period.
- **Last updated:** 2021-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03041116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03041116, "Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03041116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*